Iovance’s stock slides 40% after sharing data about its melanoma therapy


Shares of Iovance Biotherapeutics Inc. IOVA, +2.30% tumbled about 40% in after-hours trading on Thursday. The company had announced new clinical data for its experimental melanoma drug, including a 29% objective response rate in one cohort of patients. In that cohort, there were three complete responses and 22 partial responses, and the median duration of response was 10.4 months. Iovance also reiterated plans to file a biologics application to the Food and Drug Administration in August. The company’s stock is down 20.8% this year, while the S&P 500 SPX, +1.99% has declined 16.5%.

This article was originally published by Read the original article here.

Previous articleMarket Snapshot: Dow, S&P 500 and Nasdaq jump as consumer, tech sectors power higher
Next articleGap stock down 15% after retailer cuts profit outlook


Please enter your comment!
Please enter your name here